WO1996034975A1 - Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters - Google Patents
Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters Download PDFInfo
- Publication number
- WO1996034975A1 WO1996034975A1 PCT/US1996/005953 US9605953W WO9634975A1 WO 1996034975 A1 WO1996034975 A1 WO 1996034975A1 US 9605953 W US9605953 W US 9605953W WO 9634975 A1 WO9634975 A1 WO 9634975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azetidinone
- enzyme
- acid
- lipase
- hydrolysis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/874—Pseudomonas
- Y10S435/875—Pseudomonas aeruginosa
Definitions
- European Published Application 595,557 discloses novel substituted azetidinones of the general formula 1 as potent elastase inhibitors, which are useful as anti-inflammatory and anti- degenerative agents. These compounds may be used in the treatment of inflammatory conditions resulting in connective tissue destruction, e.g.
- rheumatoid arthritis emphysema
- bronchial inflammation chronic bronchitis
- glomerulonephritis osteoarthritis
- osteoarthritis spondylitis
- lupus psoriasis
- atherosclerosis sepsis
- septicemia shock, myocardial infarction, reperfusion injury, periodonitis, cystic fibrosis and acute respiratory distress syndrome.
- a subset of compounds disclosed in EP 595,557 are those wherein R and Rl are each ethyl, R4 is a carboxylic acid derivative such as a carboxamide, and the absolute configuration at carbon-4 of the azetidinone ring is S Qa) la
- the chiral compound I may be obtained from a racemic mixture using conventional chemical process such as by formation of a salt with an optically active base, followed by separation of the resultant diastereomers, for example by fractional crystallization.
- chemical resolution process is generally long and tedious, and it would be advantageous if a more convenient method is available for the preparation of chiral compound I.
- the present invention provides an enantioselective process for the preparation of (4S)-3,3-diethyl-4-[(4-carboxy)phenoxy]-2- azetidinone from a racemic mixture of a corresponding ester.
- the present invention concerns enzymatic hydrolysis of ester to produce optically active acid with high enantiomeric excess. More particularly, the present invention provides a novel process for the preparation of the (SJ-enantiomer of the azetidinone acid of formula I:
- R is selected from the group consisting of benzyl, and Cl-C8 alkyl, with a lipase obtained from Pseudomonas sp., and recovering said (S)-azetidinone acid.
- R of the compound of formula II is benzyl, methyl, propyl or hexyl.
- the lipase is the lipoprotein lipase PS available from Amano International Enzyme Co. (Troy, Virginia, USA). More preferably, R is benzyl.
- the lipase is derived from Pseudomonas MB5001 (ATCC 55162 ).
- the enzymatic hydrolysis is carried out in the presence of a surfactant; more preferably the surfactant is a nonionic surfactant such as alkylaryl poly ether alcohols, for example octylphenoxy polyethoxyethanol such as Triton® X-100 (available from Sigma Chemical Co.).
- a surfactant is a nonionic surfactant such as alkylaryl poly ether alcohols, for example octylphenoxy polyethoxyethanol such as Triton® X-100 (available from Sigma Chemical Co.).
- the process of the present invention provides an efficient method for the preparation of a compound of formula I with high optical purity.
- the substrates, azetidinone esters of formula II can be prepared according to the general process disclosed in US Patent 5,229,381, and as shown schematically below using the benzyl ester as an example.
- the process of the present invention may be carried out using a lipase derived from Pseudomonas sp.
- the present inventors have discovered two preferred lipases that are capable of effecting the stereoselective hydrolysis of compounds of formula II to provide the (S)- enantiomer of formula I.
- One such lipase is obtained from Pseudomonas aeruginosa MB 5001, which has been deposited in accordance with the Budapest Treaty with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD as ATCC No. 55162 and in the Merck Culture Collection as MB 5001.
- the production, isolation, purification and characterization of the lipase from this organism has been reported in the following articles:
- the second preferred lipase useful in the present method is the commercially available lipase preparation derived from Pseudomonas sp., and sold under the Amano label as lipase PS (Amano International Enzyme Co., Inc., Troy, Virginia).
- lipase PS Amano International Enzyme Co., Inc., Troy, Virginia.
- the enzymatic hydrolysis of the ester of formula II is carried out under conditions that do not impact unduly on the enzymatic activity of the lipase, or otherwise interfere with the production of the desired final product.
- the reaction is conducted in a slightly alkaline environment such as in a buffered solution having pH of about 6.5 to about 9.0; typically, a phosphate buffer of about pH 7.7 is used.
- the reaction temperature may be from about 25 °C to about 50 °C, but preferably at about 37 °C to about 40 °C.
- a surfactant is added to the reaction mixture to solubilize the substrate; preferred surfactants are nonionic surfactants such as alkylaryl polyether alcohols and the like; a more preferred surfactant is octylphenoxy polyethoxyethanol available under the name Triton® X-100 (from Sigma Chemical Co.).
- the reaction mixture is agitated to ensure contact of the substrate with the enzyme.
- the enzymatic hydrolysis is allowed to proceed for a period sufficient to generate satisfactory quantity of the desired (5)-azetidinone acid in satisfactory optical purity; typically, the time period is about 72 to about 96 hours; preferably about 96 hours.
- the amount of the desired acid produced and the optical activity may be monitored by HPLC and chiral HPLC.
- the amount of lipase used is about 5 g/1 to about 50 g/1; preferably it is about 15 to 25 g/1
- the concentration of the substrate may be from 0.1 g/1 to about 45 g/1.
- the surfactant may be used from about 0.05% to about 5%, preferably about 0.1% to about 0.5% by volume.
- the enzyme may be used as crude preparation isolated from the producing organism, in the commercially available form, or it may be immobilized on solid support.
- the desired hydrolysis product, the unreacted substrate ester, and the enzyme may be recovered from the hydrolysis mixture using convential techniques such as filtration, chromatography, crystallization, or combinations thereof.
- the recovered enzyme may be used in subsequent hydrolysis, and the recovered ester may be racemized and also reused.
- the enzymatic hydrolysis of the present invention is illustrated as follows using the benzyl ester of formula II as the substrate, and Amano lipase PS-800 as the enzyme.
- the hydrolysis in this case shows a kinetic profile that indicates a poisoning of the enzyme activity after about 96 hr, with a falloff in significant acid production.
- the profile of the enantioselectivity in the production of the desired acid shows a gradual diminishment from an initial enantiomeric excess (e.e.) of about 95% to about 88% e.e. over a 7 day hydrolysis experiment.
- the hydrolysis performed in aqueous phosphate buffer in the presence of Triton X-100 at 37 °C, is heterogeneous in terms of the benzyl ester and enzyme, while the acid and benzyl alcohol produced are solubilized.
- the mixture was then filtered through a Millipore 10 kilo-Dalton regenerated cellulose filter cartridge, which retained the enzyme and permeated the aqueous solution containing the desired (S)-acid, phosphate buffer, Triton X-100 and benzyl alcohol.
- the enzyme was recovered free of salts, Triton X-100 and benzyl alcohol, retained >90% of the original activity in the olive oil assay, and was ready for reuse.
- the aqueous permeate retained little or no enzyme activity. Filtration of the enzyme through a 30 kD filter cartridge resulted in enzyme activity equally partitioned between the retentate and permeate.
- Isolation of the (5)-acid from the permeate was achieved by isopropyl acetate extraction of the aqueous phase after adjustment to pH 5 with 5% phosphoric acid and the addition of sodium chloride. Evaporation and crystallization from t-butyl methylether (MTBE) resulted in a 90% recovery of acid 2 with 93% e.e.
- MTBE t-butyl methylether
- Recovered benzyl ester (S:R enantiomer ratio 30:70) was racemized at 40 °C as a homogeneous solution in 90% aqueous acetonitrile in the presence of about 15 mol % benzyl 4-hydroxy benzoate and about 15 mol % cesium carbonate. Isolated racemic benzyl ester was resubmitted to enzyme hydrolysis using enzyme recovered from previous hydrolysis runs. Normal hydrolysis kinetics, acid production, and enantioselectivity were observed.
- the (S)-azetidinone acid of formula I is an intermediate used in the preparation of elastase inhibitors of formula 1.
- the reaction sequence is generally disclosed in EP 337,549 and EP 595,557.
- the carbamoyl moiety is added to the azetidinone nitrogen atom by treating the azetidinone acid with an appropriate isocyanate in the presence of a base such as triethylamine.
- a base such as triethylamine.
- the resulting ⁇ -lactam urea acid in the presence of a coupling agent such as dicyclohexylcarbodiimide, or converted to an acylating equivalent thereof such as the acid chloride, is reacted with an appropriate amine, for example piperazine, to provide the final product.
- a coupling agent such as dicyclohexylcarbodiimide
- an acylating equivalent thereof such as the acid chloride
- Chiral SFC-HPLC Chiracel OD(H) (made by Chiral Technologies), 28 vol % EtOH (containing 20 mM HCIO4), 1.0 mL/min, 300 Bar, 35 °C. Retention time: (S)-acid - 7.6 min; (S)-ester - 8.3 min; (R)-acid - 9.5 min; (R)-ester- 11.6 min.
- the aqueous suspension of the enzyme in the hydrolysis medium was pumped (Cole-Parmer Masterflex centrifugal pump) at -300 mL/min through a Millipore PLTK Prep/Scale-TFF 1 ft2 10 k regenerated cellulose filter cartridge (catalogue number CDUFOOILT 10k).
- the retentate return line was restricted to allow a permeate flow of -700 mL/hr.
- the enzyme slurry was filtered through a 30 kilo- Dalton filter, half of the enzyme activity remained with the permeate.
- the permeate (3 L) was treated with 5% phosphoric acid to adjust the pH to 5.0, then sodium chloride (1.2 Kg) was added and the mixture was extracted with isopropyl acetate (3 x 200 mL). The bulk of the aqueous phase was removed and the remainder required filtration through a scintered glass funnel to remove interfacial material which prevented clean separation of the two phases.
- the combined extracts were washed with water (200 mL), evaporated to 200 mL volume and diluted to 500 mL with dry isopropyl acetate. The material was reconcentrated to 200 mL volume to azeotropically dry the solution and then filtered to remove inorganic solids.
- Example 1 The solution was combined with a second solution obtained from Example 1 (8.8 g acid), which used the recovered enzyme from Example 1 and so demonstrated the ability to recycle the enzyme, and the combined solution was evaporated to a solid.
- This material was dissolved into refluxing methyl t-butyl ether (MTBE, 200 mL), then evaporated in vacuo to -100 mL. The material began crystallizing during concentration and was aged at 20 °C for 5 hr. The mixture was filtered, washed with MTBE and dried to give 13.5 g of solids. The mother liquours were concentrated to 30 mL vol, aged for 5 hr, filtered, washed with MTBE and dried to give an additional 2.05 g of material.
- MTBE refluxing methyl t-butyl ether
- Benzyl ester (55.8 g, 92 wt %, 51.3 g by HPLC), recovered from enzyme hydrolyses as a 70:30 mixture of R:S enantiomers, was added to acetonitrile: water (90: 10, 165 mL) at 20 °C and warmed to 50 °C to give a homogeneous solution.
- benzyl 4- hydroxybenzoate (0.38 g) and cesium carbonate (0.5 g) was added. This solution was then heated and aged at 50-55 °C for six hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56330/96A AU694358B2 (en) | 1995-05-03 | 1996-04-29 | Enzymatic hydrolysis of 3,3-diethyl-4-{(4-carboxy)phenoxy}-2-azetidinone esters |
JP8533401A JP2939342B2 (en) | 1995-05-03 | 1996-04-29 | Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy) phenoxy] -2-azetidinone ester |
EP96913261A EP0826065A1 (en) | 1995-05-03 | 1996-04-29 | Enzymatic hydrolysis of 3,3-diethyl-4- (4-carboxy)phenoxy]-2-azetidinone esters |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/433,586 | 1995-05-03 | ||
US08/433,586 US5523233A (en) | 1995-05-03 | 1995-05-03 | Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996034975A1 true WO1996034975A1 (en) | 1996-11-07 |
Family
ID=23720700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/005953 WO1996034975A1 (en) | 1995-05-03 | 1996-04-29 | Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters |
Country Status (9)
Country | Link |
---|---|
US (1) | US5523233A (en) |
EP (1) | EP0826065A1 (en) |
JP (1) | JP2939342B2 (en) |
AR (1) | AR001816A1 (en) |
AU (1) | AU694358B2 (en) |
CA (1) | CA2218881A1 (en) |
HR (1) | HRP960211A2 (en) |
WO (1) | WO1996034975A1 (en) |
YU (1) | YU25996A (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69914458T2 (en) | 1998-02-17 | 2004-10-28 | G.D. Searle & Co., Chicago | METHOD FOR ENZYMATICALLY DISCHARGING LACTAS |
DE19931847A1 (en) * | 1999-07-09 | 2001-01-11 | Basf Ag | Immobilized lipase |
AT502395B1 (en) | 2005-07-27 | 2007-03-15 | Iep Gmbh | OXIDOREDUCETASES FOR THE STEREOSELECTIVE REDUCTION OF KETOVER BINDINGS |
AT503486B1 (en) * | 2006-04-11 | 2008-05-15 | Iep Gmbh | METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF STEROIDS |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0421283A2 (en) * | 1989-10-02 | 1991-04-10 | Fujisawa Pharmaceutical Co., Ltd. | A new process for preparing optically active 3-substituted azetidinones |
EP0552041A2 (en) * | 1992-01-15 | 1993-07-21 | E.R. Squibb & Sons, Inc. | Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
EP0595557A1 (en) * | 1992-10-27 | 1994-05-04 | Merck & Co. Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
-
1995
- 1995-05-03 US US08/433,586 patent/US5523233A/en not_active Expired - Lifetime
-
1996
- 1996-04-26 YU YU25996A patent/YU25996A/en unknown
- 1996-04-29 WO PCT/US1996/005953 patent/WO1996034975A1/en not_active Application Discontinuation
- 1996-04-29 EP EP96913261A patent/EP0826065A1/en not_active Ceased
- 1996-04-29 AR AR33634296A patent/AR001816A1/en unknown
- 1996-04-29 JP JP8533401A patent/JP2939342B2/en not_active Expired - Lifetime
- 1996-04-29 CA CA002218881A patent/CA2218881A1/en not_active Abandoned
- 1996-04-29 AU AU56330/96A patent/AU694358B2/en not_active Ceased
- 1996-04-30 HR HR08/433,586A patent/HRP960211A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0421283A2 (en) * | 1989-10-02 | 1991-04-10 | Fujisawa Pharmaceutical Co., Ltd. | A new process for preparing optically active 3-substituted azetidinones |
EP0552041A2 (en) * | 1992-01-15 | 1993-07-21 | E.R. Squibb & Sons, Inc. | Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
EP0595557A1 (en) * | 1992-10-27 | 1994-05-04 | Merck & Co. Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
Also Published As
Publication number | Publication date |
---|---|
HRP960211A2 (en) | 1998-02-28 |
AU5633096A (en) | 1996-11-21 |
US5523233A (en) | 1996-06-04 |
AR001816A1 (en) | 1997-12-10 |
JP2939342B2 (en) | 1999-08-25 |
CA2218881A1 (en) | 1996-11-07 |
YU25996A (en) | 1998-11-05 |
AU694358B2 (en) | 1998-07-16 |
EP0826065A1 (en) | 1998-03-04 |
JPH10507932A (en) | 1998-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0449648B1 (en) | Process for producing R(-)-mandelic acid and derivatives thereof | |
AU694358B2 (en) | Enzymatic hydrolysis of 3,3-diethyl-4-{(4-carboxy)phenoxy}-2-azetidinone esters | |
US5346828A (en) | Stereoisomeric enrichment of 2-amino-3-hydroxy-3-phenylpropionic acids using d-threonine aldolase | |
DE69023997T2 (en) | Process for the preparation of optically active 3-phenylglycidic acid esters. | |
EP0912755B1 (en) | The bioresolution of n-acylazetidine-2-carboxylic acids | |
IE912338A1 (en) | Process for producing enantiomers of 2-aryl-alkanoic acids | |
US5215919A (en) | Process for producing optically active 2-hydroxycycloalkanecarboxylic acid esters using microbially derived reductase | |
EP0237983A2 (en) | Process for the biotechnological preparation of L (-)-carnitine chloride | |
WO2004108944A1 (en) | Method for producing optically active chroman-carboxylate | |
EP2351729B1 (en) | Process for production of optically active organic carboxylic acid | |
CA2111595C (en) | Process for the enzymatic preparation of optically active transglycidic acid esters | |
US6165777A (en) | Process for the resolution of cis 1,2-indane diols using Pseudomonas putida | |
JPH0630790A (en) | Production of optically active 1,2-propanediol | |
US6153414A (en) | Method for racemic biochemical resolution of CIS-and trans-pyprolopiperidine | |
EP1290209A1 (en) | Method for preparing an r- or s-form of alpha-substituted heterocyclic carboxylic acid and a counter enantiomeric form of alpha-substituted heterocyclic carboxylic acid ester thereto using enzyme | |
US5883264A (en) | Process for preparing optically active trans-3-phenylglycidamide compounds | |
JP3732535B2 (en) | Process for producing optically active α-methylalkanedicarboxylic acid-ω-monoester and its enantiomer diester | |
US5248601A (en) | Process for preparing L(-)-carnitine chloride | |
EP1290208A1 (en) | Method for optically resolving a racemic alpha-substituted heterocyclic carboxylic acid using enzyme | |
JP3010382B2 (en) | Method for producing (R) -2-propoxybenzene derivative | |
DE602004005947T2 (en) | Process for the preparation of an optically active octahydro-1H-indole-2-carboxylic acid | |
JP3970898B2 (en) | Process for producing optically active α-methylalkanedicarboxylic acid-ω-monoester and its enantiomer diester | |
JPH08119958A (en) | Production of optically active chroman compound | |
JPH06261787A (en) | Production of optically active beta-amino acid | |
JPH0965891A (en) | Production of optically active alpha-methylalkanoic acid derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2218881 Country of ref document: CA Ref country code: CA Ref document number: 2218881 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996913261 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996913261 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1996913261 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996913261 Country of ref document: EP |